HOOKIPA Pharma Inc.

Overview

• IndustryPharmaceutical Preparations¹
• HeadquartersNew York, New York¹
• Incorporated inDE⁴
• Business address350 Fifth Avenue, 72Nd Floor, Suite 7240, New York, Ny 10118⁴
• Filer categoryNon-accelerated filer, Smaller reporting company⁴

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on our proprietary arenavirus platform that is designed to target and amplify T cell and immune responses to fight diseases. Our replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. We believe that our technologies can meaningfully leverage the human immune system therapeutic purposes by inducing CD8+ T cell response levels previously not achieved by other immune therapy approaches.⁵ From its latest annual report

Corporate structure

HOOKIPA Pharma Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What HOOKIPA Pharma Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

Our principal executive offices are located in New York, New York, pursuant to a lease that expires in August 2026. Our European research and preclinical development operations are located in Vienna, Austria, where we lease and occupy approximately 30,681 square feet of office and laboratory space. Our first Austrian facility is leased pursuant to two operating leases, comprised of (i) a lease of unlimited duration for approximately 15,239 square feet of office and laboratory space which will be terminated effective March 31, 2025 and (ii) a lease initially set to expire in September 2028 and with no option to extend for approximately 2,367 square feet of storage space which will be terminated effective June 30, 2025. In 2019, we entered into a lease for a second facility located in Vienna, Austria that was initially set to expire in February 2029, where we occupy approximately 15,440 square feet of office and laboratory space, which will be terminated effective February 28, 2025. In May 2021 we purchased a parcel of land in the north of Vienna and have received building permission to build a GMP manufacturing plant of approximately 48,440 square feet.

In January 2024 our Board decided to implement a Restructuring Plan, which included the discontinuation of the GMP manufacturing project and the divestment of all associated assets, including the parcel of land. Strategic considerations preceding the adoption of the Restructuring Plan resulted in the impairment of the full carrying value of the GMP manufacturing facility project in the year ended December 31, 2023 and the land is currently held for sale. We are currently evaluating the required space needed to meet our future need following our strategic refocus. We believe if we require new or additional space, we will be able to obtain additional facilities on commercially reasonable terms.

Item 2 of the 10-K filed Feb 28, 2025.⁵

Leadership

Who has led HOOKIPA Pharma Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMalte Peters Jul 24, 2024 to now¹⁴
• Chief executive officerJorn Aldag Apr 17, 2019 to Jul 24, 2024¹⁵
• Chief financial officerMary Theresa Coelho Jul 24, 2024 to now¹⁶
• Chief financial officerReinhard Kandera Apr 17, 2019 to Jul 24, 2024¹⁷
• Chief operating officerChristine D. Baker Jul 1, 2022 to Apr 18, 2023¹⁸

Timeline

1. Jul 29, 20258-K Shareholder vote³⁷
2. Jul 18, 20258-K Listing notice or transfer; Other events³⁸
3. May 22, 20258-K Entered a material agreement; Ended a material agreement; Executive or director change³⁹
4. Feb 20, 20258-K Other events⁴⁰
5. Jan 29, 20258-K Regulation FD disclosure⁴¹
6. Jan 10, 20258-K Other events⁴²
7. Jan 7, 20258-K Other events⁴³
8. Jan 2, 20258-K Other events⁴⁴
9. Nov 20, 20248-K Other events⁴⁵
10. Nov 14, 20248-K Results of operations⁴⁶
11. Aug 30, 20248-K Executive or director change; Regulation FD disclosure⁴⁷
12. Aug 8, 20248-K Results of operations⁴⁸
13. Jul 24, 2024New chief executive Malte Peters becomes CEO¹⁴
14. Apr 17, 2019New chief executive Jorn Aldag becomes CEO¹⁵

Calendar

When it reported results

1. Nov 14, 2024Reported quarterly or annual results⁴⁶
2. Aug 8, 2024Reported quarterly or annual results⁴⁸
3. May 9, 2024Reported quarterly or annual results⁴⁹
4. Mar 22, 2024Reported quarterly or annual results⁵⁰
5. Jan 29, 2024Reported quarterly or annual results⁵¹
6. Nov 9, 2023Reported quarterly or annual results⁵²
7. Aug 10, 2023Reported quarterly or annual results⁵³
8. May 11, 2023Reported quarterly or annual results⁵⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

219 filings to the SEC since October 2021: 6 annual reports, 11 quarterly reports, 55 major events, 67 insider forms, 27 large holders, 53 other. The latest 20:

1. Oct 9, 20254 EDGAR
2. Aug 27, 2025144/A EDGAR
3. Aug 27, 2025144 EDGAR
4. Aug 8, 202515-12G EDGAR
5. Jul 29, 2025EFFECT EDGAR
6. Jul 29, 2025EFFECT EDGAR
7. Jul 29, 202525 EDGAR
8. Jul 29, 2025S-8 POS EDGAR
9. Jul 29, 2025S-8 POS EDGAR
10. Jul 29, 2025S-8 POS EDGAR
11. Jul 29, 2025S-8 POS EDGAR
12. Jul 29, 2025POS AM EDGAR
13. Jul 29, 2025POS AM EDGAR
14. Jul 29, 20258-K EDGAR
15. Jul 23, 20254 EDGAR
16. Jul 23, 20254 EDGAR
17. Jul 18, 20258-K EDGAR
18. Jul 7, 2025UPLOAD EDGAR
19. Jul 3, 2025DEFM14A EDGAR
20. Jun 30, 2025CORRESP EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 7 buys and 4 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• EcoR1 Capital, LLCSCHEDULE 13G/A, 6 filings Apr 8, 2022 to Feb 14, 2025⁵⁵
• SOFINNOVA CAPITAL VI FCPRSCHEDULE 13D/A, 2 filings Feb 13, 2023 to Feb 14, 2025⁵⁶
• Invus Global Management, LLCSC 13G/A, 1 filing Aug 2, 2024⁵⁷
• Artal International S.C.A.SC 13G, 1 filing Jul 8, 2024⁵⁸
• BAKER BROS. ADVISORS LPSC 13D, 3 filings Feb 14, 2023 to Jun 14, 2024⁵⁹
• Redmile Group, LLCSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 2024⁶⁰
• Gilead SciencesSC 13G/A, 3 filings Feb 17, 2022 to Dec 22, 2023⁶¹
• FMR LLCSC 13G/A, 4 filings Feb 9, 2022 to Sep 11, 2023⁶²
• Knoll Capital Management, LLCSC 13G, 1 filing Jun 20, 2023⁶³
• Deep Track Capital, LPSC 13G/A, 2 filings Mar 4, 2022 to Feb 14, 2023⁶⁴
• Forbion Capital Fund II Cooperatief U.A.SC 13G/A, 1 filing Feb 11, 2022⁶⁵

SEC filer profile

How HOOKIPA Pharma Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARHOOKIPA Pharma Inc.¹
• CIK0001760542
• Employer ID (EIN)81-5395687⁵
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁵
• Incorporated inDelaware⁵
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address350 Fifth Avenue, 72Nd Floor, Suite 7240, New York, NY 10118¹
• Phone0114318906360¹
• Shares outstanding9,659,522 Common Stock Other Than Class shares; 2,399,517 Common Class A shares as of Feb 24, 2025⁵
• Public float$57.0M as of Jun 30, 2024⁵
• AuditorPwC Wirtschaftsprüfung GmbH, Vienna, Austria PCAOB ID 1259; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceDec 14, 2018¹
• Filings395 in all: 4 (139), 8-K (73), 3 (28), SC 13G/A (24), 10-Q (19), SC 13G (12), DEFA14A (9), CORRESP (7)¹
  All 47 form types

  EFFECT (7), UPLOAD (7), 10-K (6), 424B5 (6), DEF 14A (5), S-3 (4), S-8 (4), S-8 POS (4), SC 13D/A (4), 10-K/A (2), 4/A (2), ARS (2), DRS/A (2), POS AM (2), PRE 14A (2), SC 13D (2), 144 (1), 144/A (1), 15-12G (1), 25 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), CT ORDER (1), D (1), DEFM14A (1), DEL AM (1), DRS (1), DRSLTR (1), FWP (1), PREM14A (1), PRER14A (1), S-1 (1), S-1/A (1), SC TO-I (1), SC TO-I/A (1), SCHEDULE 13D/A (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (10-K) Feb 28, 2025
  Quarterly report (10-Q) May 15, 2025
  Proxy statement (DEF 14A) Apr 26, 2024
  Latest 8-K (8-K) Jul 29, 2025

Securities registered for trading

From the cover page of the 10-K filed Feb 28, 2025 (Section 12(b) of the Exchange Act).⁵

Risk factors and legal proceedings

The risks HOOKIPA Pharma Inc. names in Item 1A of its 10-K filed Feb 28, 2025: 73 risks under these headings, as written.⁵

• Risks Related to Our Financial Position and Capital Needs
• We are a clinical-stage biopharmaceutical company with no approved products and a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.
• There is substantial doubt regarding our ability to continue as a going concern. We will need to raise substantial additional funding, which may not be available on acceptable terms, if at all, to be able to continue as a going concern and advance any our product candidates. Failure to obtain capital when needed may force us to delay, limit or terminate our product development efforts or other operations. Raising additional capital may dilute our existing shareholders, restrict our operations or cause us to relinquish valuable rights.
• We will require substantial additional financing and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.
• Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights.
• If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders if we issue equity securities, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
• We have obtained funding from an agency of the Austrian government that contains certain covenants that may restrict our operations.
• Risks Related to Our Business and Industry
• If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.
• The regulatory approval processes of the FDA, the EMA and the European Commission and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
• Our clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.
• Our preclinical programs may experience delays or our product candidates may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.

Legal proceedings

We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.

The opening of Item 3, Legal Proceedings.⁵